Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.90 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.68 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.45 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL1585734 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL7676355 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL14485411 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL14485408 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL11046268 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL6129075 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL1585733 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL9007523 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL6564498 | 1.00 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL25241602 | 0.95 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007503382-A | — | — | 2007-02-22 | — | — | JP | claimed |
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | DIATOS S.A. (FR) | 2006-12-14 | — | — | US | claimed |
| EP-1701743-A2 | POTENTIATION OF THE ACTIVATION OF HIGH-MOLECULAR-MASS PRODRUGS | Diatos (FR) | 2006-09-20 | — | — | EP | claimed |
| WO-2005021043-A2 | HIGH-MOLECULAR-MASS PRODRUGS | DIATOS (FR) | 2005-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | CD44, MMP12, FOLH1 | SLC7A5 523/4885SLC1A2 2536/4885SLC1A3 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.